Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process

Molecules

Volumn 19, Issue 12, 2014, Pages 20325-20339

  Ha, Eun Sol ^a   Choo, Gwang Ho ^a   Baek, In Hwan ^b   Kim, Min Soo ^a  

^a Pusan National University   (South Korea)

^b Kyungsung University   (South Korea)

Author keywords

Bioavailability; Celecoxib; Nanoparticles; Solid dispersion; Supercritical antisolvent

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NANOPARTICLE; POVIDONE; PYRAZOLE DERIVATIVE; SULFONAMIDE; SURFACTANT;

ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; MEDICINAL CHEMISTRY; PARTICLE SIZE; RAT; SOLUBILITY; ULTRASTRUCTURE; X RAY DIFFRACTION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG COMPOUNDING; NANOPARTICLES; PARTICLE SIZE; POVIDONE; PYRAZOLES; RATS; SOLUBILITY; SULFONAMIDES; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION;

EID: 84919741170     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191220325     Document Type: Article

References (32)

1. Clemett, D.; Goa, K.L. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000, 59, 957-980.
2. Seedher, N.; Bhatia, S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003, 4, 36-44.
3. Nasr, M. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats. AAPS PharmSciTech 2013, 14, 719-726.
4. Song, W.H.; Park, J.H.; Yeom, D.W.; Ahn, B.K.; Lee, K.M.; Lee, S.G.; Woo, H.S.; Choi, Y.W. Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation. Arch. Pharm. Res. 2013, 36, 69-78.
5. Nguyen, T.H.; Tan, A.; Santos, L.; Ngo, D.; Edwards, G.A.; Porter, C.J.; Prestidge, C.A.; Boyd, B.J. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation. J. Control. Release 2013, 167, 85-91.
6. Ha, E.S.; Ok, J.; Noh, J.; Jeong, H.Y.; Choo, G.H.; Jung, Y.S.; Baek, I.H.; Kim, J.S.; Cho, W.; Hwang, S.J.; et al. Fabrication and evaluation of celecoxib microparticle surface modified by hydrophilic cellulose and surfactant. Int. J. Biol. Macromol. 2015, 72, 1473-1478.
7. Dolenc, A.; Kristl, J.; Baumgartner, S.; Planinsek, O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 2009, 376, 204-212.
8. Nagarsenker, M.S.; Joshi, M.S. Celecoxib-cyclodextrin systems: Characterization and evaluation of in vitro and in vivo advantage. Drug Dev. Ind. Pharm. 2005, 31, 169-178.
9. Baek, I.H.; Kim, M.S. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem. Pharm. Bull. 2012, 60, 1468-1473.
10. Ha, E.S.; Baek, I.H.; Cho, W.; Hwang, S.J.; Kim, M.S. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique. Chem. Pharm. Bull. 2014, 62, 545-551.
11. Palanisamy, M.; Khanam, J. Effect of physiochemical variables on phase solubility and dissolution behavior of indomethacin solid dispersion system. J. Pharm. Invest. 2014, 44, 147-162.
12. Jiang, Y.R.; Zhang, Z.H.; Liu, Q.Y.; Hu, S.Y.; Chen, X.Y.; Jia, X.B. Preparation, characterization, and in vivo evaluation of tanshinone IIA solid dispersions with silica nanoparticles. Int. J. Nanomedicine 2013, 8, 2285-2293.
13. Kim, M.S.; Kim, J.S.; Cho, W.; Cha, K.H.; Park, H.J.; Park, J.; Hwang, S.J. Supersaturatable formulations for the enhanced oral absorption of sirolimus. Int. J. Pharm. 2013, 445, 108-116.
14. Yasuji, T.; Takeuchi, H.; Kawashima, Y. Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv. Drug Deliv. Rev. 2008, 60, 388-398.
15. Kim, M.S. Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures. Int. J. Nanomedicine 2013, 8, 2029-2039.
16. Kim, M.S.; Kim, J.S.; Park, H.J.; Cho, W.K.; Cha, K.H.; Hwang, S.J. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int. J. Nanomedicine 2011, 6, 2997-3009.
17. Kim, M.S.; Kim, J.S.; Cho, W.; Park, H.J.; Hwang, S.J. Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers. Int. J. Biol. Macromol. 2013, 59, 138-142.
18. Ha, E.S.; Choo, G.H.; Baek, I.H.; Kim, J.S.; Cho, W.; Jung, Y.S.; Jin, S.E.; Hwang, S.J.; Kim, M.S. Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant. Int. J. Biol. Macromol. 2015, 72, 188-222.
19. Kim, M.S.; Baek, I.H. Fabrication and evaluation of valsartan polymer surfactant composite nanoparticles using supercritical antisolvent process. Int. J. Nanomedicine 2014, 9, 5167-5176.
20. Park, J.; Cho, W.; Kang, H.; Lee, B.B.J.; Kim, T.S.; Hwang, S.J. Effect of operating parameters on PVP/tadalafil solid dispersions prepared using supercritical anti-solvent process. J. Supercrit. Fluids 2014, 90, 126-133.
21. Park, J.; Cho, W.; Cha, K.H.; Ahn, J.; Han, K.; Hwang, S.J. Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process. Int. J. Pharm. 2013, 441, 50-55.
22. Jesson, G.; Brisander, M.; Andersson, P.; Demirbüker, M.; Derand, H.; Lennernäs, H.; Malmsten, M. Carbon dioxide-mediated generation of hybrid nanoparticles for improved bioavailability of protein kinase inhibitors. Pharm. Res. 2014, 31, 694-705.
23. Adeli, E. A comparative evaluation between utilizing SAS supercritical fluid technique and solvent evaporation method in preparation of Azithromycin solid dispersions for dissolution rate enhancement. J. Supercrit. Fluids 2014, 87, 9-21.
24. Abu-Diak, O.A.; Jones, D.S.; Andrews, G.P. An investigation into the dissolution properties of celecoxib melt extrudates: Understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol. Pharm. 2011, 8, 1362-1371.
25. Shimpi, S.L.; Mahadik, K.R.; Paradkar, A.R. Study on mechanism for amorphous drug stabilization using gelucire 50/13. Chem. Pharm. Bull. 2009, 57, 937-942.
26. Gupta, P.; Kakumanu, V.K.; Bansal, A.K. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm. Res. 2004, 21, 1762-1769.
27. Mosquera-Giraldo, L.I.; Trasi, N.S.; Taylor, L.S. Impact of surfactants on the crystal growth of amorphous celecoxib. Int. J. Pharm. 2014, 461, 251-257.
28. Khan, K.A.; Rhodes, C.T. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm. Acta Helv. 1972, 47, 594-607.
29. Gao, P.; Shi, Y. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J. 2012, 14, 703-713.
30. Warren, D.B.; Benameur, H.; Porter, C.J.; Pouton, C.W. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J. Drug Target. 2010, 18, 704-731.
31. Montes, A.; Gordilo, M.D.; Pereyra, C.; de la Rosa-Fox, N.; Martínez de la Ossa, E.J. Silica microparticles precipitation by two processes using supercritical fluids. J. Supercrit. Fluids 2013, 75, 88-93.
32. Tenorio, A.; Gordilo, M.D.; Pereyra, C.; Martínez de la Ossa, E.J. Controlled submicro particle formation of ampicillin by supercritical antisolvent precipitation. J. Supercrit. Fluids 2007, 40, 308-316.